Early Intervention for Cerebral Palsy in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone offer immediate care for newborns with neurological disorders such as cerebral palsy.
Early Intervention for Newborns with Spina Bifida | NYU Langone Health
Neonatal specialists at Hassenfeld Children’s Hospital at NYU Langone provide immediate care for newborns with severe forms of spina bifida.
Early Signs: digital phenotyping to identify digital biomarkers for predicting burnout and cognitive functioning in ED clinicians
We are looking for participants for a prospective research study titled "Early Signs: digital phenotyping to identify digital biomarkers for predicting burnout and cognitive functioning in ED clinicians” to evaluate the well-being and mental health of Emergency Department staff using innovative digital technology such as Artificial Intelligence-based video analysis. We are also interested in learning about your experiences working in the Emergency Department during the COVID-19 pandemic. If you are a full time ED staff member you may be eligible for this study. PARTICIPATION: Participation in the Early Signs study is voluntary and confidential. This study involves: 1) a recorded 15-minute audio/video interview, 2) questionnaires focused on your well-being, 3) blood and hair samples, along with a blood pressure measurement, and 4) CANTAB Neurocognitive tests. For interested participants, the study duration is 3 years, which includes an annual on-site visit at NYU Grossman School of Medicine along with 6-month virtually conducted follow-ups in between. Participating in the Early Signs study will have no impact on your standing as an employee. Early Signs is an NYU Grossman School of Medicine Institutional Review Board (IRB) approved study. COMPENSATION: You will be reimbursed up to $900. CONTACT: Should you have any questions about the study, please feel free to contact a member of the research team Dr. Katharina Schultebraucks at EarlySigns@nyulangone.org or Joseph Chang at 646-754-4943 or Joseph.chang@nyulangone.org.
Eating Disorders | NYU Langone Health
NYU Langone doctors offer expert care for eating disorders, including anorexia nervosa, bulimia nervosa, and binge eating disorder.
Eating Disorders in Children & Adolescents | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone provide expert care for children and teens with eating disorders.
Eating Disorders Service | NYU Langone Health
The Eating Disorders Service at the Child Study Center is part of Hassenfeld Children’s Hospital at NYU Langone.
Eczema & Dermatitis | NYU Langone Health
Dermatologists at NYU Langone are specialists in diagnosing and treating the types of skin irritation known as eczema and dermatitis.
Educational Resources for Children with Cancer & Blood Disorders | NYU Langone Health
At NYU Langone’s Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders, we aid children’s education during treatment.
Edwards PASCAL TrAnScatheter Mitral Valve RePair System Pivotal Clinical Trial (CLASP IID): A prospective multicenter randomized controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR)
The goal of this study is to assess the safety and performance of the PASCAL System in patients with symptomatic degenerative mitral regurgitation (DMR) who are at prohibitive risk for mitral valve surgery (the risk to you is so high that surgery is not an option). Mitral valve regurgitation is a condition in which the mitral valve does not close completely, causing blood to leak back into the left atrium of the heart. This increases the workload on the heart and if left untreated, can increase the risk of heart failure. The PASCAL and MitraClip Systems are designed to reduce the amount of mitral regurgitation without the need for surgery (less invasive). It is unknown whether the amount of reduction in regurgitation that is achieved using either device implant system will result in a comparable benefit to you. The PASCAL System is an investigational (experimental) device. This means it has not yet approved by the U.S. Food and Drug Administration (FDA). The MitraClip System is approved in the United States to treat patients with DMR who are determined to be at prohibitive risk for surgery.
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A prospective multicenter randomized controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASC
The goal of this study is to assess the safety and performance of the PASCAL System compared to the MitraClip System in patients with symptomatic moderate to severe mitral regurgitation who may not be ideal candidates for mitral valve surgery and may be eligible for transcatheter mitral valve repair. Mitral regurgitation (MR) is a condition when your heart’s mitral valve does not close tightly which causes blood to flow backwards in your heart. This condition increases the workload on the heart and if left untreated, it can increase the risk of worsening heart failure.